title: Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity.
authors.forename: L
authors.initials: L
authors.lastname: Zahiragic
authors.forename: C
authors.initials: C
authors.lastname: Schliemann
authors.forename: R
authors.initials: R
authors.lastname: Bieker
authors.forename: N H
authors.initials: NH
authors.lastname: Thoennissen
authors.forename: K
authors.initials: K
authors.lastname: Burow
authors.forename: C
authors.initials: C
authors.lastname: Kramer
authors.forename: M
authors.initials: M
authors.lastname: Zühlsdorf
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
authors.forename: R M
authors.initials: RM
authors.lastname: Mesters
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab